24. The Delegation of Australia presented the paper prepared after consulting with France, New Zealand, United Kingdom, United States, the European Commission and COMISA. The objectives of the paper had been: to identify the extent of problems in relation to injection site residues; to review the different ways these problems were being addressed and the need for harmonization; and to propose how to proceed.
25. Several Delegations shared the concerns identified in the paper about possible health risks posed by ingesting meat containing injection site residues and the implications of such residues for international trade of meat. It was noted that potential problems could arise from the use of drugs with acute toxicity or potent pharmacological activity, or those causing allergic reactions.
26. The Committee requested the Delegation of Australia, in collaboration with Canada, France, Germany, New Zealand, Switzerland, United Kingdom, United States, the EC and COMISA, to prepare a paper for consideration by the Committee at its next session. The paper should include guidance for determining the classes or formulations of drugs that would cause such problems and proposed draft guidelines for dealing with injection site residues. The principles of risk analysis should be considered in addressing these issues.
